Repro Med Systems Stock Performance
| KRMD Stock | USD 5.72 0.33 6.12% |
On a scale of 0 to 100, Repro Med holds a performance score of 13. The company holds a Beta of 0.27, which implies not very significant fluctuations relative to the market. As returns on the market increase, Repro Med's returns are expected to increase less than the market. However, during the bear market, the loss of holding Repro Med is expected to be smaller as well. Please check Repro Med's treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Repro Med's historical price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Repro Med Systems are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady primary indicators, Repro Med exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.10) | Five Day Return (5.93) | Year To Date Return (3.92) | Ten Year Return 1.1 K | All Time Return 4.8 K |
1 | KORU Medical Systems, Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/12/2025 |
2 | KORU Medical Systems, Inc. Q3 2025 Earnings Call Transcript | 11/14/2025 |
3 | KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE Syringe Infusion System in Infusion Centers at ESIDEHASIOPE Focused Symposium 20... | 11/17/2025 |
4 | Disposition of 41000 shares by Manko Joseph M. Jr. of Repro Med subject to Rule 16b-3 | 11/26/2025 |
5 | Koru Medical names Eric Schiller CTO - TipRanks | 12/16/2025 |
6 | Heres Why You Should Retain INSP Stock in Your Portfolio Now | 12/22/2025 |
7 | Insider Trading | 12/29/2025 |
8 | Acquisition by Manko Joseph M. Jr. of 2581 shares of Repro Med subject to Rule 16b-3 | 12/31/2025 |
9 | Acquisition by Fletcher R John of 3872 shares of Repro Med at 5.81 subject to Rule 16b-3 | 01/02/2026 |
10 | KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results Achieves Record Revenue and Full Year Positive Operating Cash Flow | 01/12/2026 |
11 | KORU Medical Systems Receives FDA 510 Clearance for Delivery of RYSTIGGO , Expanding Label for FreedomEDGE Infusion System | 01/29/2026 |
| Begin Period Cash Flow | 11.5 M | |
| Total Cashflows From Investing Activities | -1.3 M |
Repro Med Relative Risk vs. Return Landscape
If you would invest 386.00 in Repro Med Systems on November 4, 2025 and sell it today you would earn a total of 153.00 from holding Repro Med Systems or generate 39.64% return on investment over 90 days. Repro Med Systems is currently generating 0.6148% in daily expected returns and assumes 3.7319% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Repro, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Repro Med Target Price Odds to finish over Current Price
The tendency of Repro Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.72 | 90 days | 5.72 | about 27.01 |
Based on a normal probability distribution, the odds of Repro Med to move above the current price in 90 days from now is about 27.01 (This Repro Med Systems probability density function shows the probability of Repro Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Repro Med has a beta of 0.27. This indicates as returns on the market go up, Repro Med average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Repro Med Systems will be expected to be much smaller as well. Additionally Repro Med Systems has an alpha of 0.4483, implying that it can generate a 0.45 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Repro Med Price Density |
| Price |
Predictive Modules for Repro Med
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Repro Med Systems. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Repro Med Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Repro Med is not an exception. The market had few large corrections towards the Repro Med's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Repro Med Systems, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Repro Med within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.45 | |
β | Beta against Dow Jones | 0.27 | |
σ | Overall volatility | 0.80 | |
Ir | Information ratio | 0.12 |
Repro Med Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Repro Med for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Repro Med Systems can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Repro Med Systems appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 33.65 M. Net Loss for the year was (6.07 M) with profit before overhead, payroll, taxes, and interest of 24.35 M. | |
| Repro Med Systems currently holds about 18.27 M in cash with (319.72 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: KORU Medical Systems Receives FDA 510 Clearance for Delivery of RYSTIGGO , Expanding Label for FreedomEDGE Infusion System |
Repro Med Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Repro Stock often depends not only on the future outlook of the current and potential Repro Med's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Repro Med's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 45.8 M | |
| Cash And Short Term Investments | 9.6 M |
Repro Med Fundamentals Growth
Repro Stock prices reflect investors' perceptions of the future prospects and financial health of Repro Med, and Repro Med fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Repro Stock performance.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0921 | ||||
| Profit Margin | (0.1) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 247.67 M | ||||
| Shares Outstanding | 46.32 M | ||||
| Price To Earning | 11.56 X | ||||
| Price To Book | 15.33 X | ||||
| Price To Sales | 6.39 X | ||||
| Revenue | 33.65 M | ||||
| Gross Profit | 24.35 M | ||||
| EBITDA | (5.67 M) | ||||
| Net Income | (6.07 M) | ||||
| Cash And Equivalents | 18.27 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 3.99 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 5.40 X | ||||
| Book Value Per Share | 0.36 X | ||||
| Cash Flow From Operations | (319.72 K) | ||||
| Earnings Per Share | (0.08) X | ||||
| Market Capitalization | 249.68 M | ||||
| Total Asset | 27.22 M | ||||
| Retained Earnings | (29.38 M) | ||||
| Working Capital | 11.93 M | ||||
| Current Asset | 2.54 M | ||||
| Current Liabilities | 516.46 K | ||||
About Repro Med Performance
By analyzing Repro Med's fundamental ratios, stakeholders can gain valuable insights into Repro Med's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Repro Med has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Repro Med has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 95.56 | 176.79 | |
| Return On Tangible Assets | (0.26) | (0.25) | |
| Return On Capital Employed | (0.29) | (0.28) | |
| Return On Assets | (0.26) | (0.24) | |
| Return On Equity | (0.32) | (0.31) |
Things to note about Repro Med Systems performance evaluation
Checking the ongoing alerts about Repro Med for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Repro Med Systems help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Repro Med Systems appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 33.65 M. Net Loss for the year was (6.07 M) with profit before overhead, payroll, taxes, and interest of 24.35 M. | |
| Repro Med Systems currently holds about 18.27 M in cash with (319.72 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: KORU Medical Systems Receives FDA 510 Clearance for Delivery of RYSTIGGO , Expanding Label for FreedomEDGE Infusion System |
- Analyzing Repro Med's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Repro Med's stock is overvalued or undervalued compared to its peers.
- Examining Repro Med's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Repro Med's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Repro Med's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Repro Med's stock. These opinions can provide insight into Repro Med's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Repro Stock analysis
When running Repro Med's price analysis, check to measure Repro Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repro Med is operating at the current time. Most of Repro Med's value examination focuses on studying past and present price action to predict the probability of Repro Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repro Med's price. Additionally, you may evaluate how the addition of Repro Med to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |